Alzamend Neuro, Inc.
ALZN
$2.22
-$0.14-5.93%
NASDAQ
| 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.72% | -11.50% | -31.59% | -48.52% | -55.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.45% | -54.75% | -66.04% | -61.53% | -51.99% |
| Operating Income | 15.45% | 54.75% | 66.04% | 61.53% | 51.99% |
| Income Before Tax | 15.57% | 54.61% | 65.92% | 61.42% | 51.89% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 15.57% | 54.61% | 65.92% | 61.42% | 51.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 15.57% | 54.61% | 65.92% | 61.42% | 51.89% |
| EBIT | 15.45% | 54.75% | 66.04% | 61.53% | 51.99% |
| EBITDA | 15.76% | 55.03% | 66.34% | 61.77% | 52.24% |
| EPS Basic | 90.64% | 85.63% | 83.45% | 71.21% | 54.55% |
| Normalized Basic EPS | 91.65% | 86.36% | 83.53% | 71.27% | 54.55% |
| EPS Diluted | 90.64% | 85.63% | 83.45% | 71.21% | 54.55% |
| Normalized Diluted EPS | 91.65% | 86.36% | 83.53% | 71.27% | 54.55% |
| Average Basic Shares Outstanding | 1,120.95% | 499.30% | 294.49% | 117.91% | 8.11% |
| Average Diluted Shares Outstanding | 1,120.95% | 499.30% | 294.49% | 117.91% | 8.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |